Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Authors

Junsheng Wang

Anyang Cancer Hospital, Anyang, China

Junsheng Wang , Tao Wu , SuXia Luo , Ning Li , Yonggui Hong , Yanzhen Guo , Yufeng Cheng , Baosheng Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.

First Author: Ning Li

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.

First Author: Junsheng Wang

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

First Author: Tiandong Kong

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.

First Author: Shui-Ling Jin